ALPS Medical Breakthroughs ETF (SBIO)
|Ex-Dividend Date||Dec 19, 2019|
|Day's Range||34.02 - 34.53|
|Inception Date||Dec 31, 2014|
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Top 10 Holdings25.47% of assets
|CRISPR Therapeutics AG||CRSP||3.20%|
|Cerevel Therapeutics Holdings||CERE||2.29%|
|Dec 19, 2019||$0.01585||Dec 27, 2019|
|Dec 20, 2018||$0.78406||Dec 27, 2018|
|Dec 21, 2017||$0.57949||Dec 28, 2017|
Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the Virtu...
Global Blood Therapeutics (NasdaqGS: GBT) shares climbed Thursday, lifting biotechnology sector-related exchange traded funds, on speculation of takeover bids for the small drug developer. On Thursday, ...
A surge in biotech stocks that began in mid-June is lasting longer than skeptics expected, with no signs of slowing down. The ALPS Medical Breakthroughs ETF (SBIO) gained 7.74% in June as positive drug ...
The ALPS Medical Breakthroughs ETF (SBIO) rallied 11.53% last week on positive trial data and merger and acquisition news that revived the biotech sector. The small- and mid-cap biotech companies among...
In financial markets, it's often said that cash is king. That's something to remember when it comes to the biotechnology universe due to the cost-intensive nature of developing new drugs and therapies.
These funds can take some of the risks out of these exciting but sometimes dangerous sectors.
Among the most beaten-down assets in the first month of 2022 were biotechnology stocks, with smaller members of that group enduring significant punishment. That's the bad news.
Expectations are in place for a brisk pace of consolidation in the biotechnology space this year, and that could benefit an assortment of exchange traded funds, such as the ALPS Medical Breakthroughs ET...
Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.
Biotechnology stocks are healthcare laggards this year, and much of the lagging is concentrated in the small- and mid-cap biotech spaces. However, retail traders are embracing some speculative small-cap...
The S&P 500 Health Care Index is up almost 16% year-to-date. That's a solid showing to be sure, but biotechnology stocks and exchange traded funds are still waiting on their moments.
Sector ETF report for SBIO